[HTML][HTML] Notch signaling pathway: architecture, disease, and therapeutics

B Zhou, W Lin, Y Long, Y Yang, H Zhang… - Signal transduction and …, 2022 - nature.com
The NOTCH gene was identified approximately 110 years ago. Classical studies have
revealed that NOTCH signaling is an evolutionarily conserved pathway. NOTCH receptors …

Targeting signalling pathways and the immune microenvironment of cancer stem cells—a clinical update

JA Clara, C Monge, Y Yang, N Takebe - Nature reviews clinical …, 2020 - nature.com
Cancer stem cells (CSCs) have important roles in tumour development, relapse and
metastasis; the intrinsic self-renewal characteristics and tumorigenic properties of these cells …

[HTML][HTML] The Notch signaling pathway: a potential target for cancer immunotherapy

X Li, X Yan, Y Wang, B Kaur, H Han, J Yu - Journal of hematology & …, 2023 - Springer
Dysregulation of the Notch signaling pathway, which is highly conserved across species,
can drive aberrant epigenetic modification, transcription, and translation. Defective gene …

[HTML][HTML] EMT-mediated acquired EGFR-TKI resistance in NSCLC: mechanisms and strategies

X Zhu, L Chen, L Liu, X Niu - Frontiers in Oncology, 2019 - frontiersin.org
Acquired resistance inevitably limits the curative effects of epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR-TKIs), which represent the classical paradigm of molecular …

[HTML][HTML] The strategies to cure cancer patients by eradicating cancer stem-like cells

Y Mai, J Su, C Yang, C Xia, L Fu - Molecular Cancer, 2023 - Springer
Cancer stem-like cells (CSCs), a subpopulation of cancer cells, possess remarkable
capability in proliferation, self-renewal, and differentiation. Their presence is recognized as a …

[HTML][HTML] Drug resistance in non-small cell lung cancer: a potential for NOTCH targeting?

V Sosa Iglesias, L Giuranno, LJ Dubois, J Theys… - Frontiers in …, 2018 - frontiersin.org
Drug resistance is a major cause for therapeutic failure in non-small cell lung cancer
(NSCLC) leading to tumor recurrence and disease progression. Cell intrinsic mechanisms of …

Gamma secretase inhibitors in cancer: a current perspective on clinical performance

TR McCaw, E Inga, H Chen, R Jaskula‐Sztul… - The …, 2021 - academic.oup.com
Gamma secretase inhibitors (GSIs), initially developed as Alzheimer's therapies, have been
repurposed as anticancer agents given their inhibition of Notch receptor cleavage. The …

Clinical activity of the γ-secretase inhibitor PF-03084014 in adults with desmoid tumors (aggressive fibromatosis)

S Kummar, G O'Sullivan Coyne, KT Do… - Journal of Clinical …, 2017 - ascopubs.org
Purpose Desmoid tumors (aggressive fibromatosis) arise from connective tissue cells or
fibroblasts. In general, they are slow growing and do not metastasize; however, locally …

[HTML][HTML] Ovarian cancer stem cells and targeted therapy

V Keyvani, M Farshchian, SA Esmaeili, H Yari… - Journal of ovarian …, 2019 - Springer
Background Ovarian cancer has the highest ratio of mortality among gynecologic
malignancies. Chemotherapy is one of the most common treatment options for ovarian …

[HTML][HTML] First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer

C Massard, A Azaro, JC Soria, U Lassen… - Annals of …, 2018 - Elsevier
Abstract Background Deregulated Notch signaling due to mutation or overexpression of
ligands and/or receptors is implicated in various human malignancies. γ-Secretase inhibitors …